Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Masanori Onda, Richard Beers, Laiman Xiang, Byungkook Lee, John E Weldon, Robert J Kreitman, Ira Pastan
Author Information
  1. Masanori Onda: Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.

Abstract

Many nonhuman proteins have useful pharmacological activities, but are infrequently effective in humans because of their high immunogenicity. A recombinant immunotoxin (HA22, CAT8015, moxetumomab pasudotox) composed of an anti-CD22 antibody variable fragment fused to PE38, a 38-kDa portion of Pseudomonas exotoxin A, has produced many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can be given, but has much less activity when antibodies develop. We have pursued a strategy to deimmunize recombinant immunotoxins by identifying and removing B-cell epitopes. We previously reported that we could eliminate most B-cell epitopes using a combination of point mutations and deletions. Here we show the location and amino acid composition of all of the B-cell epitopes in the remaining 25-kDa portion of Pseudomonas exotoxin. Using this information, we eliminated these epitopes to produce an immunotoxin (HA22-LR-8M) that is fully cytotoxic against malignant B-cell lines, has high cytotoxic activity against cells directly isolated from patients with chronic lymphocytic leukemia, and has excellent antitumor activity in mice. HA22-LR-8M does not induce antibody formation in mice when given repeatedly by intravenous injection and does not induce a secondary antibody response when given to mice previously exposed to HA22. HA22-LR-8M also has greatly reduced antigenicity when exposed to sera from patients who have produced antibodies to HA22. The properties of HA22-LR-8M make it an excellent candidate for further clinical development.

References

  1. Clin Cancer Res. 2000 Apr;6(4):1476-87 [PMID: 10778980]
  2. Circulation. 1996 Jul 15;94(2):197-206 [PMID: 8674179]
  3. J Immunother. 2010 Apr;33(3):297-304 [PMID: 20445350]
  4. Clin Cancer Res. 2002 Apr;8(4):995-1002 [PMID: 11948105]
  5. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6 [PMID: 18678888]
  6. J Clin Oncol. 2000 Apr;18(8):1622-36 [PMID: 10764422]
  7. Blood. 2000 Aug 15;96(4):1425-32 [PMID: 10942387]
  8. Nat Rev Cancer. 2006 Jul;6(7):559-65 [PMID: 16794638]
  9. Curr Pharm Biotechnol. 2002 Dec;3(4):349-60 [PMID: 12463417]
  10. Br J Cancer. 2004 Jun 14;90(12):2402-10 [PMID: 15162148]
  11. Toxicol Sci. 2004 Feb;77(2):280-9 [PMID: 14691215]
  12. Methods Mol Biol. 2004;248:503-18 [PMID: 14970517]
  13. Eur J Immunol. 1997 Jun;27(6):1459-68 [PMID: 9209499]
  14. N Engl J Med. 1987 Mar 5;316(10):589-96 [PMID: 3807953]
  15. Clin Cancer Res. 2005 Feb 15;11(4):1545-50 [PMID: 15746059]
  16. Biotechniques. 1990 May;8(5):528-35 [PMID: 2357375]
  17. Methods. 2005 May;36(1):3-10 [PMID: 15848070]
  18. N Engl J Med. 2001 Jul 26;345(4):241-7 [PMID: 11474661]
  19. Bioconjug Chem. 2007 May-Jun;18(3):773-84 [PMID: 17346030]
  20. J Immunol. 2000 Dec 15;165(12):7150-6 [PMID: 11120846]
  21. J Immunol. 2004 Jun 1;172(11):6658-65 [PMID: 15153481]
  22. Drug Discov Today. 2004 Jan 15;9(2):82-90 [PMID: 15012932]
  23. Cancer Res. 2008 Aug 1;68(15):6300-5 [PMID: 18676854]
  24. Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [PMID: 17785569]
  25. J Immunol. 2006 Dec 15;177(12):8822-34 [PMID: 17142785]
  26. Cancer Res. 2001 Jul 1;61(13):5070-7 [PMID: 11431343]
  27. N Engl J Med. 2002 Feb 14;346(7):469-75 [PMID: 11844847]
  28. Blood. 2009 Apr 16;113(16):3792-800 [PMID: 18988862]
  29. J Clin Oncol. 2009 Jun 20;27(18):2983-90 [PMID: 19414673]
  30. Clin Cancer Res. 2009 Aug 15;15(16):5274-9 [PMID: 19671873]
  31. Circulation. 1996 Jul 15;94(2):207-16 [PMID: 8674180]

Grants

  1. /Intramural NIH HHS

MeSH Term

ADP Ribose Transferases
Amino Acid Sequence
Animals
Antibodies, Monoclonal
Bacterial Toxins
Cell Line, Tumor
Enzyme-Linked Immunosorbent Assay
Epitopes, B-Lymphocyte
Exotoxins
Immunization, Passive
Leukemia, Lymphocytic, Chronic, B-Cell
Mice
Mice, Inbred BALB C
Models, Molecular
Molecular Sequence Data
Mutagenesis
Protein Engineering
Recombinant Fusion Proteins
Statistics, Nonparametric
Virulence Factors
Pseudomonas aeruginosa Exotoxin A

Chemicals

Antibodies, Monoclonal
Bacterial Toxins
Epitopes, B-Lymphocyte
Exotoxins
Recombinant Fusion Proteins
Virulence Factors
immunotoxin HA22
ADP Ribose Transferases

Word Cloud

Created with Highcharts 10.0.0B-cellepitopesHA22-LR-8MmiceimmunotoxinHA22antibodygivenactivityhighimmunogenicityrecombinantportionPseudomonasexotoxinproducedleukemiaantibodiespreviouslycytotoxicpatientsexcellentinduceexposedManynonhumanproteinsusefulpharmacologicalactivitiesinfrequentlyeffectivehumansCAT8015moxetumomabpasudotoxcomposedanti-CD22variablefragmentfusedPE3838-kDamanycompleteremissionsdrug-resistanthairy-cellseveralcyclesagentcanmuchlessdeveloppursuedstrategydeimmunizeimmunotoxinsidentifyingremovingreportedeliminateusingcombinationpointmutationsdeletionsshowlocationaminoacidcompositionremaining25-kDaUsinginformationeliminatedproducefullymalignantlinescellsdirectlyisolatedchroniclymphocyticantitumorformationrepeatedlyintravenousinjectionsecondaryresponsealsogreatlyreducedantigenicityserapropertiesmakecandidateclinicaldevelopmentRecombinantmalignanciesremoval

Similar Articles

Cited By